Niyondiko, N. (2024) Clinical Management of Diabetic Ketoacidosis in Pregnancy: A Review of Current Literature. Open Access Library Journal, 11, 1-25. doi: 10.4236/oalib.1112246 .
New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...
Etiology and Treatment Advances of Hematochezia in Infants Aged ≤3 Months. Journal of Biosciences and Medicines, 12, 273-285. doi: 10.4236/jbm.2024.1211023 . Acute intussusception is most prevalent in ...
Immunoglobulin 4-related disease (IgG4-RD) is known for its potential to affect nearly every organ, particularly a preference for large and middle-sized arteries when vascular involvement occurs.
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...
Case Presentation 5: My Fascinoma of the Year: A Rich Emotional Experience. Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials. ObesityWeek 2024 is being held November 3-6, 2024, in San Antonio, Texas. One presentation will ...
Presentation to focus on use of validated ... 23, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic ...